Key words: HAPA-B, AMK, Comparative study, Respiratory tract infections
|
|
|
- ときな かいて
- 6 years ago
- Views:
Transcription
1
2 Key words: HAPA-B, AMK, Comparative study, Respiratory tract infections
3 Fig. 1 Chemical structure of HAPA-B
4 Table 1 Collaborating clinics The First Department of Internal Medicine, Kyorin University, School of Medicine The Second Department of Internal Medicine, School of Medicine, Hokkaido University The First Department of Internal Medicine, Asahikawa Medical College Department of Internal Medicine, Iwamizawa Rohsai Hospital The 3rd Internal Medicine, Hirosaki University, School of Medicine The Third Department of Internal Medicine, School of Medicine, Iwate Medical University Respiratory Division, Iwaki Kyoritsu General Hospital Department of Internal Medicine, Kasumigaura National Hospital The Second Department of Internal Medicine, The Jikei University School of Medicine Department of Chest Medicine, National Medical Center Hospital The First Department of Internal Medicine, School of Medicine, Showa University Department of Internal Medicine, Kawasaki Municipal Hospital Department of Internal Medicine, Kawasaki Chuo Hospital First Department of Internal Medicine, Yokohama City University, School of Medicine Department of the Chest, Kanagawa Prefectural Nagahama Hospital Department of Internal Medicine, Shinrakuen Hospital Department of Internal Medicine, Toyama Prefectural Central Hospital The First Department of Internal Medicine, Toyama Medical and Pharmaceutical University The First Department of Internal Medicine, Nagoya University, School of Medicine The First Department of Internal Medicine, Nagoya City University, School of Medicine Respiratory Division, Nagahama Red Cross Hospital Division of Respiratory Medicine, Shiga Medical Center for Adult Disease Department of Internal Medicine, Moriyama City Hospital Department of Internal Medicine, Public Koga Hospital Department of Respiratory Disease, Kyoto City Hospital Respiratory Division, Kyoto Katsura Hospital Department of Internal Medicine, Saiseikai Ibaraki Hospital Department of Internal Medicine, Tane General Hospital The Fourth Department of Internal Medicine, Kinki University, School of Medicine Division of Respiratory Diseases Department of Medicine, Kawasaki Medical School The Second Department of Internal Medicine, Hiroshima University, School of Medicine The First Department of Internal Medicine, Faculty of Medicine, and School of Health Sciences, Kyushu University Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University Clinical Research Division, The National Minami Fukuoka Chest Hospital The Second Department of Internal Medicine, Medical College of Oita The Second Department of Internal Medicine, Nagasaki University School of Medicine Department of Internal Medicine, Institute for Tropical Medicine, Nagasaki University The First Department of Internal Medicine, Kumamoto University, School of Medicine Department of Internal Medicine, Kumamoto Municipal Hospital Department of Internal Medicine, National Kirishima Hospital
5
6
7 Table 2 Criteria for judgement of usefulness by committee members
8 Table 3 Criteria for evaluation of clinical symptoms
9 Table 4 Case distribution Table 5 Reasons for exclusion from evaluation of clinical effectiveness
10 Table 6 Diagnosis judged by committee members Table 7 Background of patients-characteristics of patients (1)-
11 Table 8 Background of patients-characteristics of patients (2)- a) Malignant tumor, congestive heart failure, central nervous disturbance, diabetes mellitus, chronic respiratory disease b) Diseases other than A group Table 9 Background of patients-initial symptoms (1)-
12 Table 9 (continued) Table 10 Background of patients-initial symptoms (2)-
13 Table 11 Background of patients-initial chest X-ray findings (Pneumonia)- Table 12 Background of patients-causative bacteria-
14 Table 13 Background of patients-susceptibility of causative bacteria- Table 14 Duration of medication Fig. 2 Clinical effectiveness judged by committee members
15 Table 15 Clinical effectiveness judged by committee members Table 16 Clinical effectiveness judged by committee members classified by initial severity
16 Table 17 Clinical effectiveness judged by committee members classified by causative bacteria
17 Table 18 Clinical effectiveness judged by committee members classified by age-all Table 19 Clinical effectiveness judged by committee members classified by age-chronic cases- RTI-
18 Table 20 Clinical effectiveness judged by committee members classified by ESR-Pneumonia- Table 21 Bacteriological response classified by causative bacteria-all cases-
19 Table 21 (continued)
20 Table 22 Bacteriological response classified by causative bacteria-pneumonia-
21 Table 23 Bacteriological response classified by causative bacteria-chronic RTI-
22 Table 24 Causative bacteria and isolated bacteria after treatment Fig. 3 Profile of symptomatic improvement All cases
23 Fig. 4 Profile of symptomatic improvement Pneumonia Table 25 Improvement of chest X-ray findings -Pneumonia-
24 Fig. 5 Profile of symptomatic improvement Chronic RTI Table 26 Clinical effectiveness judged by bedside doctors in charge
25 Fig. 6 Clinical effectiveness judged by bedside doctors in charge Table 27 Side effects judged by committee members
26 Table 28 Abnormal changes in laboratory findings judged by committee members Table 29 Usefulness judged by committee members
27 Table 30 Usefulness judged by bedside doctors in charge
28
29 2) Morohoshi, T., Toriya, M., Yokoiyama, S., Fujimoto, K., Hayano, K., Goto, S. & Tsuji, A.: The acetylation of 6'-amino group of amikacin by a new enzyme prepared from Serratia sp. J. Antibiotics, 37: , 1984.
30 Comparison of HAPA-B and Amikacin in the Treatment of Respiratory Tract Infections Hiroyuki KOBAYASHI, Hiroshi OSHITANI & Masahiko YOSHIDA The First Department of Internal Medicine, Kyorin University, School of Medicine Akira SAITO & Ichiro NAKAYAMA The Second Department of Internal Medicine, School of Medicine, Hokkaido University Sokichi ONODERA & Nobuhiro SASAKI The First Department of Internal Medicine, Asahikawa Medical College Fumio NAGAHAMA*, Yomei HIRAGA, Takehito NAKABAYASHI, Kyuichiro SEKINE & Jutaro SHIMOMURA Department of Internal Medicine, Iwamizawa Rohsai Hospital and Related Hospitals (* Present address: Sapporo National Hospital) Kazuo TAKEBE, Shiro KOSAKA, Mitsuo MASUDA, Seiichi MURAKAMI, Kenichi KIMURA, Hideaki KASHIWAMURA & Keiko GASA The 3rd Internal Medicine, Hirosaki University, School of Medicine and Related Hospitals Masao TAMURA, Kazuki KONISHI, Takashi ITO, Yoshikatsu NEMOTO, Hiroshi KURAMITSU & Kazutoshi GOMI The Third Department of Internal Medicine, School of Medicine, Iwate Medical University and Related Hospitals Izumi HAYASHI Respiratory Division, Iwaki Kyoritsu General Hospital Masataka KATSU, Hajime YAMAGATA & Minoru SATOH Department of Internal Medicine, Kasumigaura National Hospital Yasushi UEDA The Jikei University School of Medicine Atsushi SAITO & Tadashi MIYAHARA The Second Department of Internal Medicine, The Jikei University School of Medicine Junzaburo KABE, Koichiro KUDOH, Yasuyuki SANO & Michiko HAIDA Department of Chest Medicine, National Medical Center Hospital Terumi TAKAHASHI & Keita KASAHARA The First Department of Internal Medicine, School of Medicine, Showa University Ippei FUJIMORI, Yoshio KOBAYASHI & Seiji MITA Department of Internal Medicine, Kawasaki Municipal Hospital Takeshi MITSUI Department of Internal Medicine, Kawasaki Chuo Hospital Takao OKUBO & Akira ITO First Department of Internal Medicine, Yokohama City University, School of Medicine Shigeki ODAGIRI, Kaneo SUZUKI & Koou MUROHASHI Department of the Chest, Kanagawa Prefectural Nagahama Hospital Osamu SEKINE, Yoshimaru USUDA & Nobuki AOKI Department of Internal. Medicine, Shinrakuen Hospital
31 Kaoru OYAMA Department of Internal Medicine, Toyama Prefectural Central Hospital Naohiro YAMASHITA & Saburo YANO The First Department of Internal Medicine, Toyama Medical and Pharmaceutical University Kaoru SHIMOKATA, Yoshihiro SENDA, Yoshio TORII, Saizi YOSHII, Keisuke NISHIWAKI & Osamu KOHNOU The First Department of Internal Medicine, Nagoya University, School of Medicine and Related Hospitals Masahito KATO, Joichi KATO, Hidekazu HANAKI & Toshihiko TAKEUCHI The First Department of Internal Medicine, Nagoya City University, School of Medicine and Related Hospitals Kikuo SUGIMOTO Respiratory Division, Nagahama Red Cross Hospital Kazue SHIMADA & Takafumi FUKUNAGA Division of Respiratory Medicine, Shiga Medical Center for Adult Disease Kisao SATAKE Department of Internal Medicine, Moriyama City Hospital Hikaru OHTA & Toshio NISHIMURA Department of Internal Medicine, Public Koga Hospital Michiro NAKASHIMA Department of Respiratory Disease, Kyoto City Hospital Sadao IKEDA Respiratory Division, Kyoto Katsura Hospital Hidehiro NANBA Department of Internal Medicine, Saiseikai Ibaraki Hospital Fumio MIKI, Yoshiyasu IKUNO, Eiji INOUE, Minoru YOSHIYAMA, Tooru HIRAGA & Akihito MURATA Department of Internal Medicine, Tane General Hospital Shigenori NAKAJIMA, Yasuo TSUYA & Hiroki UENISHI The Fourth Department of Internal Medicine, Kinki University, School of Medicine Rinzo SOEJIMA, Hiroshi KAWANE, Yoshihito NIKI, Susumu YAGI & Masaru SUMI Division of Respiratory Diseases Department of Medicine, Kawasaki Medical School Michiro YAMAKIDO, Akimitsu KAMITSUNA, Masakazu ITASAKA & Kenji HASEGAWA The Second Department of Internal Medicine, Hiroshima University, School of Medicine Yoshiro SAWAE, Kaoru OKADA & Yukio KUMAGAI The First Department of Internal Medicine, Faculty of Medicine, and School of Health Sciences, Kyushu University Shinichiro HAYASHI & Nobuaki SHIGEMATSU Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University Hitoshi NAGANO, Chiharu KUBO & Masahito KARIYA Clinical Research Division, The National Minami Fukuoka Chest Hospital Masaru NASU, Jun GOTO & Yoichiro GOTO The Second Department of Internal Medicine, Medical College of Oita Kohei HARA, Atsushi SAITO, Keizo YAMAGUCHI, Yoshiteru SHIGENO, Shigeru KOHNO, Toshiyuki OE, Kiyo FUJITA, Yasuko UEDA & Kota KOHNO The Second Department of Internal Medicine, Nagasaki University School of Medicine and Related Hospitals Keizo MATSUMOTO, Toshiaki YOSHIDA & Kazunori OISHI Department of Internal Medicine, Institute for Tropical Medicine, Nagasaki University Shukuro ARAKI, Masayuki ANDO & Moritaka SUGA The First Department of Internal Medicine, Kumamoto University, School of Medicine
32 Kiyoshi SHIMA, Yasutsugu FUKUDA, Katsumasa TOKUNAGA, Shinobu TAKENAKA, Sadanobu HIGUCHI, Ryuji FUJISE, Jiro TAMIYA, Yuichi MOTOZATO, Kiyotaka ITO & Kiyonori ITSUNO Department of Internal Medicine, Kumamoto Municipal Hospital and Related Hospitals Takehiko SAKURAMI & Kunio FUJISAKI Department of Internal Medicine, National Kirishima Hospital The clinical effectiveness, safety and usefulness of HAPA-B, a new aminoglycoside, in the treatment of respiratory tract infections were compared with those of amikacin (AMK) ina double blind study. The following diseases were included in this study; bacterial pneumonia, pulmonary suppression, infectious exacerbation of chronic bronchitis and diffuse panbronchiolitis and chronic respiratory tract diseases with infection (bronchiectasis, pulmonary emphysema, lung fibrosis, bronchial asthma). HAPA-B and AMK were intramusculary administered twice a day for 14 days, at a daily dose of 400 mg of both drugs (one ampoule containing 200 mg). The following results were obtained. 1) Case distribution Total cases administered HAPA-B or AMK were 218 patients. Out of these cases, 185 patients (HAPA-B 98, AMK 87) were evaluated on clinical effectiveness, 207 (HAPA-B 108, AMK 99) on side effects, 193 (HAPA-B 102, AMK 91) on laboratory findings, 182 (HAPA-B 96, AMK 86) on usefulness. 2) Clinical effectiveness Out of 98 patients in HAPA-B group, one patient was judged as "Excellent", 65 as "Good", 9 as "Fair", 23 as "Poor" and the efficacy rate was 67.3%. On the other hand, out of 87patients in AMK group, one patient was judged as "Excellent", 56 as "Good", 10 as "Fair", 20 as "Poor" and the efficacy rate was 65.5%. There was no significant difference between two groups. However, the improvement rates of HAPA-B group in cough, dyspnea and volume of sputum were significantly superior to those of AMK at 3rd or 7th day after administration. 3) Bacteriological effect Bacteriologically, the eradication rate of 60.6% was observed out of 66 clinical isolates in HAPA-B group and it was 59.5% in 42 clinical isolates in AMK group. There was no significant difference between two groups. 4) Side effects and abnormal changes in laboratory findings Side effects were observed in 3 of 108 patients (2.8%) with HAPA-B and 6 of 99 patients (6.1%) with AMK. Allergic symptoms were observed in both groups but pain at the injection site and dizziness were observed only in AMK group. Abnormal changes in laboratory findings were observed in 20 of 102 patients (19.6%) with HAPA-B and 27 of 91 patients (29.7%) with AMK after administration. Elevations of BUN and s-creatinine were observed only in AMK group, while eosinophilia and elevation of transaminases were observed in both groups. There was no significant difference between two groups. 5) Usefulness The usefulness of HAPA-B group was 65.6% and that of AMK was 62.8% judged by committee members. The usefulness judged by doctors in charge of HAPA-B group was 65.2% and that of AMK was 54.8%. There was no significant difference between two groups. 6) From the above results, it was concluded that clinical effectiveness of HAPA-B was at least equal to that of AMK in the treatment of respiratory tract infections and because of no adverse reaction to renal and auditory functions, HAPA-B was considered to be a useful aminoglycoside.
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
CHEMOTHERAPY Silver sulfadiazine (T 107) CHEMOTHERAPY Fig. 1 Item of patients Table 1 Criteria of bacteriological efficacy by the Committee xcellent: E Score of infection becomes to 0% at the end of medication.
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
Key words: RU 28965, roxithromycin, midecamycin acetate Pneumonia, double-blind method
Key words: RU 28965, roxithromycin, midecamycin acetate Pneumonia, double-blind method Fig. 1 Chemical structure of RU Table 1 Evaluation criteria for signs, symptoms and laboratory findings 1) M: mucous
Fig. 1 Chemical structure of Flurbiprofen Molecular formula : C1S H13 F02 Molecular weight : Chemical name : 2-( 2 -fluoro - 4 -biphenyly1 ) pr
Key words : Flurbiprofen, Acute Upper Respiratory Tract Inflammation, Double-Blind Clinical Evaluation Fig. 1 Chemical structure of Flurbiprofen Molecular formula : C1S H13 F02 Molecular weight : 244.27
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
Fig. 1 Chemical structure of norfioxacin (AM-715)
Fig. 1 Chemical structure of norfioxacin (AM-715) Table 1 Serum and biliary concentration of norfloxacin (AM-715) Table 2 Protocol for clinical evaluation of norfloxacin (AM-715) in the treatment of biliary
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
Key words: Norfloxacin (NFLX), Infectious enteritis, Double-blind method
Key words: Norfloxacin (NFLX), Infectious enteritis, Double-blind method Fig. 1 Chemical structure Norfloxacin (NFLX) Pipemidic acid (PPA) Fig. 2 Package of test drugs Table 1 Criteria for evaluation
Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic
COMPARATIVE CLINICAL EFFECT OF AMIKACIN AND GENTAMICIN ON COMPLICATED URINARY TRACT INFECTIONS BY DOUBLE-BLIND METHOD Tsuneo Nishiura and Yukimichi Kawada Department of Urology, Gifu University School
CHEMOTHERAPY MAY. 1988
CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
Key words: HAPA-B, Intravenous drip infusion, Fundamental and clinical investigation
Key words: HAPA-B, Intravenous drip infusion, Fundamental and clinical investigation Fig. 1 Chemical structure of HAPA-B Table 1 Background of 9 patients with Ccr value Table 2 Collaborating Clinics Internal
Key words: Respiratory tract infections, Comparative study, Cefodizime, Cefotaxime
Key words: Respiratory tract infections, Comparative study, Cefodizime, Cefotaxime Fig. 1 Chemical structure of Cefodizime Table 1 Collaborating clinics The Third Department of Internal Medicine, Hirosaki
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
Fig. 1 Chemical structure of norfloxacin Table 1. Institutes attended to the study The Department of Dermatology, Defense Medical College The Department of Dermatology, School of Medicine, Teikyo University
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
Title 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊
Title 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊澤, 淨一 ; 武井, 実根雄 Citation 泌尿器科紀要 (1990), 36(10): 1233-1252
CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
Key words: Respiratory tract infections, comparative study, ceftriaxone, cefotaxime
Key words: Respiratory tract infections, comparative study, ceftriaxone, cefotaxime Table 1 Stability of CTRX and CTX Fig.1 Items and Schedule of Laboratory Test indispensable ~: should be performed as
Key words: bacterial pneumonia, cefepime, ceftazidime, comparative study
Key words: bacterial pneumonia, cefepime, ceftazidime, comparative study Staphylococcus aureus, Streptococcus influenzae, S. pneumoniae, Klebsiella Fig. 1 Chemical structure of cefepime Table 1 Clinical
Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s
Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s Vesical irritability without urinary Pain. Pyuria 10/
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE
CHEMOTHERAPY MAY 1992
CHEMOTHERAPY MAY 1992 Fig. 1. Package of test drugs. CHEMOTHERAPY MAY 1992 VOL.40 S-3 Table 1. Items and schedule of laboratory tests CHEMOTHERAPY MAY 1992 Table 2. Evaluation criteria of symptoms, signs
Osamu NEMOTO, M.D. Clinical and Bacteriological Research of Sucrose/ Povidone-Iodine Ointment (U-PASTA kowa) for Pressure Sores and Skin Ulcers Osamu Nemoto Department of Dermatology,Tonan Hosptal
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
Table 1. Influence of urine ph on MBCs of new quinolones against Escherichia coli NIHJ JC-2 and Pseudomonas aeruginosa 18S; MBCs in urine were compared with those in Miieller-Hinton broth. Table 2. Influence
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
Key Words: Cefuzonam, Cefotiam Bacterial Pneumoniae Comparative study
Key Words: Cefuzonam, Cefotiam Bacterial Pneumoniae Comparative study Fig. 1 Chemical structure of CZON Table 1 Collaborating clinics Division of Respiratory Diseases, Department of Medicine, Kawasaki
Table 1.Distribution and number of cases with acute upper respiratory tract infections classified according to antimicrobial agents administered Table 2. Distribution of cases which were enrolled to set
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy
400 CHEMOTHERAPY JAN Table 1 Cases of drop outs
VOL. 23 NO. 1 CHEMOTHERAPY 399 Fig. 1 Stracture of cephradine Chemical name : 7-CD(-)-2-amino-2-(1,4-cyclohexadien-1-y1) -acetamido) -3-methyl-8-oxo-5-thia-1-aza- -bicyclo [4. 2. 0] oct-2-ene-2-carboxylic
Takeji NISHIKAWA, M. D.*, Takashi HARADA, M. D.** and Tatsuya IZUML M. D. Toshiyuki SUGI, M. D. Hiroshi HANYAKU, M. D. Shun-ichi MIYAKAWA, M. D. and Masaru TANAKA, M. D. Nobuko INAMOTO, M. D. and Hironori
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
JUNE 2000
VOL.48 NO.6 JUNE 2000 VOL.48 NO.6 Fig. 1. Chemical structure of pazufloxacin and pazufloxacin mesilate. JUNE 2000 VOL.48 NO.6 JUNE 2000 Table 1. Items and schedule of laboratory tests VOL.48 NO.6 Table
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
Fig.1Chemical structure of AC-1370 Table1Collaborating clinics Divisionof Respiratory Diseases,Department of Medicine,Kawasaki Medical School The Second Department of Internal Medicine,Hokkaido University
VOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
CHEMOT HERAPY
CHEMOT HERAPY CHEMOT HERAPY NOV. 1973 Table 1 Co-laboratory clinics CHEMOT HIRAPY 1537 CHEMOT HERAPY NOV. 1973 CHEMOT HERAPY 1539 Table 3 Distribution by age groups No significant difference in age and
1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
Table1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
Table 1 Classification of female patients with vealcal irritating symptom by their signs Urination pain with other vesical irritability or not Table 2 Serum levels of DL-8280 after a single oral administration
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
04-c-„FŒ{›xŒ¾-4.01
544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli
Key words: atypical pulmonary mycobacteriosis, Mycobacterium avium complex, bronchial washing, transbronchial lung biopsy Table 1 Background data of 14 patients Old pul. tbc: sclerosing pulmonary tuberculosis
Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990 a) Y Taguchi, personal communication b) M. Hayase, personal communicatio
Key words: Legionella pneumonia, culture-positive, Japanese patients Legionella (L. pneumophila (L. micdadei, L. bozemanii, Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990
udc-3.dvi
49 UDC 371.279.1 3 4 753 1 2 2 1 2 47 6 2005 11 14 50 No.35, 2006 1 1.1 AO 2003 2004 2005 2005 1 1 2005 1998 1999 2002 12 11 2000 SAT ACT Law School Admission Test LSAT Medical College Admission Test MCAT
Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo
Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
Fig. 1 Chemical structure Lomefloxacin(LFLX,NY-198) Pipemidic acid(ppa)
Key words : Lomefloxacin (LFLX, NY-198), Infectious enteritis, Double blind method Fig. 1 Chemical structure Lomefloxacin(LFLX,NY-198) Pipemidic acid(ppa) Fig. 2 Package of test drugs LFLX group PPA group
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad
Key words: Female with bladder irritability, Subjective symptoms, Pyuria, Bacteriuria Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution
1) Chemical name: Fig. 1 Chemical structure of TE-031 (-)-(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2, PYranosyl)oxy]-14-ethyl-12,13-dihydroxy-7-meth 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexo- oxy-3,5,7,9,11,13-hexamethy1-6-[[3,4,6-trideoxy-3-
Table 1 Method of administration Inactive placebo. Table 2 Critoria for overall ef4fficy rating by committee L Severity and scores of main symptoms 1) Acute tonsillitis (Peritonsillids, Peritonsillar abscess)
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
CHEMOTHERAPY JAN Fig. 1 Structure of cephradine
VOL. 23 NO. 1 CHEMOTHERAPY 409 CHEMOTHERAPY JAN. 1975 Fig. 1 Structure of cephradine VOL. 23 NO. 1 CHEMOTHERAPY 411 Table 1 Reason for drop-out 412 CHEMOTHERAPY JAN. 1975 VOl. 23 NO. 1 CHEMOTHERAPY 413
明海大学歯学雑誌 ３７‐２／１．秦泉寺
J Meikai Dent Med 37, 153 158, 8 153 1 7 5ml /1 min Wong-Baker Face Rating Scale FS 5 1 9. g 3 5ml /1 min, FS 1 66 6ml /1 min FS 5 1 9. g 3 6ml /1 min, FS 3 Two Cases of Xerostomia that Showed an Improvement
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
Key words: Respiratory Tract Infection, Ceftazidime, Cefotiam, Double-blind Method
Key words: Respiratory Tract Infection, Ceftazidime, Cefotiam, Double-blind Method Fig. 1 Chemical structure of CAZ Table 1 Result of assay on CAZ and CTM samples Table 2 Laboratory examination Table
Table 1 The list of collaborator clinics Table 5 Distribution by body weight Table 4 Distribution by age and sex groups Sex : N. S. Age : N. S. Table 6 Diagnosis classified by committee members Table
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
Special IssueOncology Nutrition Reviews Proceeding DNA β Nutrition and physical activity and the prevention of cancer Yutaka Taketani Department of Clinical Nutrition, Institute of Health Biosciences,
日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
EVALUATION OF NOCTURNAL PENILE TUMESCENCE (NPT) IN THE DIFFERENTIAL DIAGNOSIS OF IMPOTENCE Masaharu Aoki, Yoshiaki Kumamoto, Kazutomi Mohri and Kazunori Ohno Department of Urology, Sapporo Medical College
Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhe
Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhei Kobayashi*2, Mamoru Nishimuta*2, Michiyuki Shimizu*3,
Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3
第６１巻５・６号（１２月号）／特集１頁目（本刷）
Special Issue 1Sudden cardiac death symposium in Tokushima Special Issue 2How to do for your health? Reviews Original Epidemiologic problems of sudden death of school children in Tokushima Prefecture
CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
VOL.31 S-2 CHEMOT HERAPY 101 Table 1 Breakdown of cases Table 2 List of excluded cases Table 3 List of drop-out cases 102 CHEMOT HERAPY JULY 1983 Table 4 Background factors of suppurative otitis media
CHEMOTHERAPY Table 2 Clinical response of 6059-S by infection Table 3 Effect of 6059-S on blood chemistry *Normal range : S-GOT 20 `60 mu/ml, S-GPT 5 `25 IU/L, Al-Pase 30 `85 mu/ml In oilier cases : S-GOT
Key words: pazufloxacin, infectious enteritis, antibacterial activity, fecal concentration, fecal microflora : Table 1-1 Criteria for bacteriological efficacy of pazufloxacin on Shigella spp. and V. cholerae
Key words: Antibodies to Leptospira, Tokyo, Uveitis
Key words: Antibodies to Leptospira, Tokyo, Uveitis Fig. 1 Distribution of Antibody Titers in Age Decade Fig. 3 Distribution of Antibody Titers in each Strain Fig. 2 Correlation between Antibody Titers
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K
OCT. 1986 Fig. 1 Chemical structure of CVA-K VOL.34 S-4 heart infusion broth (Difco) 37.0 g, Resazurin 0.1% alcoholic solution (Wako) 1.0 ml, L-Cystein-HCl H2O (Wako) 0.5 g, Bact agar (Difco) 1.0 g, Deionized
1) Lysozyme and Viral Infections, 2nd Intern- Symposium on Fleming's Lysozyme, ational Milano, Apr. 1961. 2) Ermol'eva, Z.V. et al.: Experimental study and clinical application of lysozyme. Fed. Proc.
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486